Intrinsic value of Coherus Oncology, Inc. (CHRS)
Live fair value data for Coherus Oncology, Inc. (CHRS) is currently unavailable. Please check again shortly.
Current Price: $194.00
Valuation: Undervalued
Confidence: 6.5/10
Visual Bar
This intrinsic value is calculated using 5 different models based on projected revenue growth, profit margins, and a standard discount rate.
Is Coherus Oncology, Inc. (CHRS) undervalued or overvalued?
Based on the current model output, Coherus Oncology, Inc. appears to be undervalued with a upside of 22.00%.
Fair value vs market price — Coherus Oncology, Inc. (CHRS)
Unlock premium access to view the live fair value comparison against current market price for CHRS.
Frequently Asked Questions - CHRS
How is CHRS intrinsic value estimated?
We combine revenue growth, discount rate, and terminal growth assumptions to estimate a fair value range for CHRS.
Is CHRS undervalued or overvalued right now?
CHRS is currently shown as undervalued based on the difference between market price and intrinsic value.
How should I use the confidence score?
The confidence score (0 to 10) indicates model certainty from available inputs. Higher values suggest stronger model consistency, not a guarantee of returns.
Related companies — intrinsic value
Peers for CHRS: open their intrinsic value pages.